Topics

Clinical Trials About "2019 Dysthymia Clinical Trials Guide Companies Drugs Phases" RSS

06:29 EST 21st February 2020 | BioPortfolio

We list hundreds of Clinical Trials about "2019 Dysthymia Clinical Trials Guide Companies Drugs Phases" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "2019 Dysthymia Clinical Trials Guide Companies Drugs Phases" on BioPortfolio

We have published hundreds of 2019 Dysthymia Clinical Trials Guide Companies Drugs Phases news stories on BioPortfolio along with dozens of 2019 Dysthymia Clinical Trials Guide Companies Drugs Phases Clinical Trials and PubMed Articles about 2019 Dysthymia Clinical Trials Guide Companies Drugs Phases for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 2019 Dysthymia Clinical Trials Guide Companies Drugs Phases Companies in our database. You can also find out about relevant 2019 Dysthymia Clinical Trials Guide Companies Drugs Phases Drugs and Medications on this site too.

Showing "2019 Dysthymia Clinical Trials Guide Companies Drugs Phases" Clinical Trials 1–25 of 16,000+

Relevant

Patient Perceptions and Willingness to Enroll in Clinical Trials

The objective of our study is to determine which factors affect willingness to participate in gynecologic oncology clinical trials. Women with a diagnosis of gynecologic malignancy will be approached to complete a survey assessing willingness to participate in clinical trials. The validated Attitudes and Randomized Trials Questionnaire (ARTQ) will be used to assess willingness to participate.


Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus

In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.

Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia

To evaluate the safety and efficacy of humanized Meplazumab for Injection in patients infected by 2019-nCoA.


Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients

The new coronavirus pneumonia is an acute infectious pneumonia. The pathogen is a previously unknown new coronavirus, namely 2019 new coronavirus (2019 novel coronavirus, 2019 nCoV). However, there is no specific anti-viral drug. It has been found that the specific antibodies against virus antigen are produced after these patients were cured, which could block the infection of 2019 nCoV on the host cells. At present, immunoadsorption is the most direct, rapid and effective meth...

A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)

Objective To determine the efficacy and safety of arbidol in patients with 2019 Novel Coronavirus (2019-nCoV).Methods Patients with 2019-nCoV were divided into three groups according to randomized double-blinded controlled clinical trial principle.Patients in three groups were administrated with arbidol,200mg,tid or arbidol,400 mg,tid or not for 5 days respectively. Other antiviral and comprehensive treatments of the three groups of patients are consistent. Then investigators w...

The "ToPIC" Study = Tool to Improve Participation In Clinical Trials

The purpose of this study is to pilot the "ToPIC" tool, a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.

A Prospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective, randomized controlled cohort study was designed to compare the efficacy of two therapeutic schemes(abidol hydrochloride,abidol hydrochloride combined with interferon atomization)in the treatment of 2019-nCoV viral pneumonia, so as to provide reliable evidence-based medicine for the treatment of viral pneumonia caused by 2019-nCoV.

Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children

The study is designed to clarify the clinical characteristics, risk factors and long-term prognosis of children with 2019-nCoV infection in China.

Severe 2019-nCoV Remdesivir RCT

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay. Given no specific antiviral therapy for 2019-nCoV infection and the ready availability of remdesvir as a potential antiviral agent, based on p...

Mild/Moderate 2019-nCoV Remdesivir RCT

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay. Given no specific antiviral therapy for 2019-nCoV infection and the availability of remdesvir as a potential antiviral agent based on pre-clin...

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

The 2019 novel coronavirus (2019-nCoV) infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. There is no confirmed antivirus therapy for people infected 2019-nCoV, most of them should receive supportive care to help relieve symptoms. For severe cases, treatment should include care to support vital organ functions. This clinical trial is to inspect the safety and ...

A Prospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basi...

PREDICT Cytomegalovirus (CMV)

The overall objective of this study is to establish a personalized test to measure individualized cytomegalovirus (CMV) specific immunity in lung transplant recipients in an effort to guide antiviral prophylaxis duration in clinical practice. Targeted participants are those: - enrolled in clinical research study CTOT-20 (Clinical Trials.gov ID: NCT02631720) who - are CMV recipient positive by serology as determined using methods in accordance with current lo...

A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia

Based on oseltamivir treatment, evaluate the efficacy and safety of ASC09/ritonavir compound tablets(ASC09F) or ritonavir tablets for 2019-nCoV infection patients.

Phase 1-2a Study of EBNA1 Inhibitor, VK-2019, in Patients With Epstein-Barr Virus-positive Nasopharyngeal Cancer

This study is a First-In-Human clinical trial to assess the safety and preliminary efficacy of VK-2019, an orally administered EBNA1 inhibitor, for the treatment of patients with advanced nasopharyngeal carcinoma.

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia

In this single-center, randomized, open-label, controlled study, the investigators will evaluate the efficacy and safety of Intravenous Immunoglobulin (IVIG) in combination with standard care for severe 2019 novel coronavirus (2019-nCoV) pneumonia.

Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection

In December 2019, a pneumonia due to a novel coronavirus (2019-nCoV) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of 2019-nCoV infection has dramatically increased, with almost 20'000 cases and more than 400 reported deaths on January, 31st 2020. Little is known on the rate of human-to-human transmission of this new coronavirus 2019-nCoV. In France, subjects with contact considered to be at high or moderate risk of viral transmiss...

Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV

In late December 2019, several local health facilities reported clusters of patients with pneumonia of unknown cause that were epidemiologically linked to a seafood and wet animal wholesale market in Wuhan, Hubei Province, China. It is now confirmed that the etiology of this outbreak is a novel coronavirus, namely, 2019-nCoV. Of critical importance is rapid and simple diagnostic method to be used in clinical settings to timely inform and refine strategies that can prevent, cont...

Increasing Access of Latinas Into Breast Cancer Clinical Trials

"Increasing Access of Latinas into Breast Cancer Clinical Trials" aims to develop and pilot test a multi-communications approach - using a culturally relevant computer video, a tailored booklet and a patient navigator (PN) - to empower Latinas to make informed decisions about breast cancer clinical trials (BCCTs). This two-year study features a cohort design with random assignment of Latina breast cancer patients from the CTRC to an intervention or usual care control group (56 ...

The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective, randomized controlled cohort study was designed to compare the efficacy of different hormone doses in the treatment of 2019-nCoV severe Pneumonia.This study explores effective treatment programs for 2019-nCoV severe pneumonia and provides a reliable evidence-based basis for the treatment.

Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"

The primary objective of this sub-study, 2019-01B, is to collect blood specimens for research use in the development and validation of a blood-based test for colorectal cancer (CRC).

Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of 2019-nCoV

The "2019-nCoV infection self-test and alert system" (hereinafter referred to as "2019-nCoV self-test applet") jointly developed by Beijing Tsinghua Changgung Hospital, Institute for precision medicine, artificial intelligence of Tsinghua University was launched on February 1,2020. Residents , according to their actual healthy situation, after answering questions online, the system will conduct intelligent analysis, make disease risk assessment and give healthcare and medical...

Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia

Serious Pneumonia and Critical Pneumonia caused by the 2019-nCOV infection greatly threats patients' life, UC-MSCs treatment has been proved to play a role in curing multiple diseases. And this study is conducted to find out whether or not it will function in 2019-nCOV infection Pneumonia.

Clinical Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China

There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.

Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials

An observational study to characterize and compare long-term clinical outcomes data collected remotely through periodic tele-visits, interactive smartphone app sessions, and web-based surveys in individuals with Parkinson's Disease (PD) who have completed the interventional phases of the STEADY-PD3 and SURE-PD3 clinical trials.


More From BioPortfolio on "2019 Dysthymia Clinical Trials Guide Companies Drugs Phases"

Quick Search